{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:59:35Z","timestamp":1792699175867,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T00:00:00Z","timestamp":1566432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00520-019-05039-x","type":"journal-article","created":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T08:02:45Z","timestamp":1566460965000},"page":"2229-2238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide"],"prefix":"10.1007","volume":"28","author":[{"given":"Mallika P.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Woodring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina M.","family":"Randazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry S.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"James E.","family":"Herndon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"McSherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Lipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4004-7834","authenticated-orcid":false,"given":"Mary Lou","family":"Affronti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,22]]},"reference":[{"issue":"5","key":"5039_CR1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/1758834016654902","volume":"8","author":"O Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman O (2016) Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis. Ther Adv Med Oncol 8(5):396\u2013406. \nhttps:\/\/doi.org\/10.1177\/1758834016654902","journal-title":"Ther Adv Med Oncol"},{"issue":"Suppl 1","key":"5039_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00520-018-4121-5","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro M (2018) Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-concluding thoughts. Support Care Cancer 26(Suppl 1):35\u201337. \nhttps:\/\/doi.org\/10.1007\/s00520-018-4121-5","journal-title":"Support Care Cancer"},{"issue":"10","key":"5039_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996. \nhttps:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"5039_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/TCRM.S122480","volume":"13","author":"ML Affronti","year":"2017","unstructured":"Affronti ML, Woodring S, Peters KB, Herndon JE 2nd, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS (2017) A phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab. Ther Clin Risk Manag 13:33\u201340. \nhttps:\/\/doi.org\/10.2147\/TCRM.S122480","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"5039_CR5","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00520-014-2136-0","volume":"22","author":"ML Affronti","year":"2014","unstructured":"Affronti ML, Schneider SM, Herndon JE 2nd, Schlundt S, Friedman HS (2014) Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. Support Care Cancer 22(7):1897\u20131905. \nhttps:\/\/doi.org\/10.1007\/s00520-014-2136-0","journal-title":"Support Care Cancer"},{"issue":"10","key":"5039_CR6","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1007\/s00520-016-3276-1","volume":"24","author":"ML Affronti","year":"2016","unstructured":"Affronti ML, Woodring S, Allen K, Kirkpatrick J, Peters KB, Herndon JE 2nd, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS (2016) Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). Support Care Cancer 24(10):4365\u20134375. \nhttps:\/\/doi.org\/10.1007\/s00520-016-3276-1","journal-title":"Support Care Cancer"},{"key":"5039_CR7","unstructured":"(NCCN) (2011, 2012) National comprehensive cancers network: clinical practice guidelines in oncology. \nhttp:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp\n\n. Accessed 2012"},{"issue":"suppl 5","key":"5039_CR8","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M (2016) Participants of the MECCC (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(suppl 5):v119\u2013v133. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdw270","journal-title":"Ann Oncol"},{"issue":"12","key":"5039_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1200\/JOP.2017.026351","volume":"13","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Bohlke K, Kris MG (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update summary. J Oncol Pract 13(12):825\u2013830. \nhttps:\/\/doi.org\/10.1200\/JOP.2017.026351","journal-title":"J Oncol Pract"},{"issue":"5","key":"5039_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00520-010-0893-y","volume":"19","author":"A Rozzi","year":"2011","unstructured":"Rozzi A, Nardoni C, Corona M, Restuccia MR, Fabi A, Bria E, Minniti G, Lanzetta G (2011) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. Support Care Cancer 19(5):697\u2013701. \nhttps:\/\/doi.org\/10.1007\/s00520-010-0893-y","journal-title":"Support Care Cancer"},{"issue":"2","key":"5039_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jpainsymman.2006.10.018","volume":"34","author":"A Molassiotis","year":"2007","unstructured":"Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manag 34(2):148\u2013159. \nhttps:\/\/doi.org\/10.1016\/j.jpainsymman.2006.10.018","journal-title":"J Pain Symptom Manag"},{"issue":"3","key":"5039_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/cncr.11540","volume":"98","author":"CG Martin","year":"2003","unstructured":"Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Cancer 98(3):645\u2013655. \nhttps:\/\/doi.org\/10.1002\/cncr.11540","journal-title":"Cancer"},{"issue":"10","key":"5039_CR13","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) European organisation for R, treatment of cancer brain T, radiotherapy G, National Cancer Institute of Canada clinical trials G (2005) radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996. \nhttps:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"issue":"28","key":"5039_CR14","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240\u20133261. \nhttps:\/\/doi.org\/10.1200\/JCO.2017.74.4789","journal-title":"J Clin Oncol"},{"issue":"4","key":"5039_CR15","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.7314\/APJCP.2016.17.4.1661","volume":"17","author":"DM Yuan","year":"2016","unstructured":"Yuan DM, Li Q, Zhang Q, Xiao XW, Yao YW, Zhang Y, Lv YL, Liu HB, Lv TF, Song Y (2016) Efficacy and safety of Neurokinin-1 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis of randomized controlled trials. Asian Pac J Cancer Prev 17(4):1661\u20131675","journal-title":"Asian Pac J Cancer Prev"},{"issue":"Suppl 1","key":"5039_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00520-018-4115-3","volume":"26","author":"M Clemons","year":"2018","unstructured":"Clemons M (2018) Guidelines versus individualized care for the management of CINV. Support Care Cancer 26(Suppl 1):11\u201317. \nhttps:\/\/doi.org\/10.1007\/s00520-018-4115-3","journal-title":"Support Care Cancer"},{"issue":"Suppl 1","key":"5039_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro M (2018) CINV: still troubling patients after all these years. Support Care Cancer 26(Suppl 1):5\u20139. \nhttps:\/\/doi.org\/10.1007\/s00520-018-4131-3","journal-title":"Support Care Cancer"},{"issue":"1","key":"5039_CR18","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.clon.2018.10.008","volume":"31","author":"M Malhotra","year":"2019","unstructured":"Malhotra M, Chandrasekahran A, Tonse R, Jalali R, Patil VM (2019) Cross-sectional study of temozolomide-induced chemotherapy-induced nausea and vomiting in patients with glioma. Clin Oncol (R Coll Radiol) 31(1):e85. \nhttps:\/\/doi.org\/10.1016\/j.clon.2018.10.008","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"9","key":"5039_CR19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.2176\/nmc.oa.2014-0413","volume":"55","author":"M Matsuda","year":"2015","unstructured":"Matsuda M, Yamamoto T, Ishikawa E, Nakai K, Akutsu H, Onuma K, Matsumura A (2015) Profile analysis of chemotherapy-induced nausea and vomiting in patients treated with concomitant Temozolomide and radiotherapy: results of a prospective study. Neurol Med Chir (Tokyo) 55(9):749\u2013755. \nhttps:\/\/doi.org\/10.2176\/nmc.oa.2014-0413","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"5039_CR20","doi-asserted-by":"crossref","unstructured":"Affronti M, Randazzo D, McSherry F, Healy P, Herndon II J, Weant M, Miller E, Lipp E, Friedman H, Peters K (2018) Review and meta-analysis of nausea and vomiting trials for malignant gliomas. In: 23rd annual scientific meeting and education day of the Society for Neuro-Oncology, New Orleans, LA. vol 6. Oxford University Press, p vi218","DOI":"10.1093\/neuonc\/noy148.903"},{"issue":"6","key":"5039_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/nop\/npz009","volume":"6","author":"Vijay M Patil","year":"2019","unstructured":"Patil VM, Chandrasekharan A, Vallathol DH, Malhotra M, Abhinav R, Agarwal P, Rajpurohit A, Tonse R, Bhattacharjee A, Jalali R (2019) Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center. Neurooncol Pract. \nhttps:\/\/doi.org\/10.1093\/nop\/npz009","journal-title":"Neuro-Oncology Practice"},{"key":"5039_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/cmar.s68102","volume":"6","author":"ML Affronti","year":"2014","unstructured":"Affronti ML, Bubalo J (2014) Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy. Cancer Manag Res 6:329\u2013337. \nhttps:\/\/doi.org\/10.2147\/cmar.s68102","journal-title":"Cancer Manag Res"},{"issue":"8","key":"5039_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699\u2013708. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1308573","journal-title":"N Engl J Med"},{"issue":"8","key":"5039_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370(8):709\u2013722. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1308345","journal-title":"N Engl J Med"},{"issue":"4","key":"5039_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","volume":"16","author":"HJ Kang","year":"2015","unstructured":"Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM (2015) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol 16(4):385\u2013394. \nhttps:\/\/doi.org\/10.1016\/S1470-2045(15)70061-6","journal-title":"Lancet Oncol"},{"issue":"6","key":"5039_CR26","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","volume":"20","author":"TL Ng","year":"2015","unstructured":"Ng TL, Hutton B, Clemons M (2015) Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist 20(6):576\u2013583. \nhttps:\/\/doi.org\/10.1634\/theoncologist.2014-0438","journal-title":"Oncologist"},{"issue":"11","key":"5039_CR27","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00520-015-2801-y","volume":"23","author":"C Hernandez Torres","year":"2015","unstructured":"Hernandez Torres C, Mazzarello S, Ng T, Dranitsaris G, Hutton B, Smith S, Munro A, Jacobs C, Clemons M (2015) Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience. Support Care Cancer 23(11):3341\u20133359. \nhttps:\/\/doi.org\/10.1007\/s00520-015-2801-y","journal-title":"Support Care Cancer"},{"issue":"8","key":"5039_CR28","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","volume":"33","author":"M Di Maio","year":"2015","unstructured":"Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33(8):910\u2013915. \nhttps:\/\/doi.org\/10.1200\/JCO.2014.57.9334","journal-title":"J Clin Oncol"},{"issue":"2","key":"5039_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.6004\/jnccn.2012.0018","volume":"10","author":"JM Salsman","year":"2012","unstructured":"Salsman JM, Grunberg SM, Beaumont JL, Rogers M, Paul D, Clayman ML, Cella D (2012) Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Cancer Netw 10(2):149\u2013157","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10","key":"5039_CR30","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/cncr.20230","volume":"100","author":"SM Grunberg","year":"2004","unstructured":"Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261\u20132268. \nhttps:\/\/doi.org\/10.1002\/cncr.20230","journal-title":"Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-05039-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-05039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T23:06:27Z","timestamp":1597964787000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-05039-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,22]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["5039"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-05039-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,22]]},"assertion":[{"value":"6 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All study processes involving human subjects were performed in accordance with the ethical standards of the institutional review board of the Duke University Medical Center. All study participants voluntarily provided written informed consent prior to study inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"Mary Lou Affronti has been supported by Eisai and Merck for investigator initiated clinical trials, served as an antiemetic expert advisory board member with Eisai for NEPA (2013\u20132014) and for Merck on an Advisory Expert Input forum (2017). Sarah Woodring, Annick Desjardins, Eric Lipp, and Elizabeth Miller received support from grant by Merck with their involvement during the conduct of the study. All other authors declare no conflict of interest at this time.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}